Dial-in Number

  • One tap mobile
    +13126266799,,3231998494# US (Chicago)
    +13462487799,,3231998494# US (Houston)
  • Dial by your location
    +1 312 626 6799 US (Chicago)
    +1 346 248 7799 US (Houston)
    +1 669 900 6833 US (San Jose)
    +1 929 436 2866 US (New York)
    +1 253 215 8782 US
    +1 301 715 8592 US
    Meeting ID: 323 199 8494
    Find your local number:

Web session

HL7 Antitrust Policy

Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).


Please include your organization in your Zoom name.

  • Click on your picture/name in Zoom
  • Click on rename
  • enter <name> - <organization>
Danielle BancroftBest Practice Software
Melva Peters Jenaker Consulting
Jean Duteau Duteau DesignX
John Hatem (Chair)Independent ConsultantX
Scott Robertson Kaiser PermanenteX
Christof GessnerHL7 Germany
Corey SpearsMITREX
Dave HillMITRE
Frank McKinneyPOCPX
Isaac VetterEpic
Joe QuinnSmile CDRX
Lawrence LoColumbia University HIT Student
Margaret WeikerNCPDPX
Matt SzczepankiewiczEpic
Peter SergentHL7 New ZealandX
Reed D. GelzerTrustworthy EHR
Shelly SpiroPharmacy HIT CollaborativeX
Stephen ChuADHAX
Tim McNeilSurescriptsX
Kim RobertsPharmacy HIT CollaborativeX
Kent BulzaWell HealthX
Phung Matthews3M
Jack BrashierEpic
Emmanuel Obasuyi

Joel MontavonPQA
Robb YoungPharmID
Christopher Isong
Gary SchoettmerNetRxX

Agenda Items and Notes

Outstanding Action Item List

Meeting Notes from previous meeting

2022-05-02 Agenda/Meeting Notes - accepted by acclimation general consent

Project Review

Project Proposals

  • Project Proposals in Review -
    • Electronic Product Information FHIR Implementation Guide
      • PSS-2090 - Getting issue details... STATUS
      • aka ePL ... online version of SPL
      • common international core profiles
      • Pharmacy as interested party, not a co-sponsor
    • Standard Patient Health Record
      • PSS-2088 - Getting issue details... STATUS
      • to be used in PHR.  and updates PHR-s Functional Model to FHIR
      • Stephen - is this needed?  no systems saving this information in native FHIR format.  Included this in our comment and asked for clarification on goals.
    • Vulcan FHIR-to-OMOP
      • PSS-1970 - Getting issue details... STATUS
      • reusable FHIR to OMOP mapping would reduce the cost and effort to generate and maintain research data warehouses.
      • Pharmacy :  not a co-sponsor, not an interested party.  offered Pharmacy input on FHIR-medication-specific questions

Project Scope Statements

External Meeting Review

Catalog Updates (John Hatem)

  • - Catalog group has been updating the example for one of the medication use cases in the IG.  Use case #6: all meds licensed for use within a jurisdiction. 

Workflow Update (John Hatem) 

  • - Discuss contract issues.  No Pharmacy specific issues discussed. 

Healthcare Product Update (John Hatem)

  • -  Discussed SupplyDelivery resource requirements.  No Pharmacy specific issues discussed. 

EHR conformant reconciled medication list (cRML)

NCPDP Updates (NCPDP Members)

WG18 Patient Consent TG:

  •  - 

MC Consumer and Provider RTPB Standards Monitoring Sub-Task Group

WG14 Consultant Pharmacist TG

  •  - 

WG18 Specialty Requirements for ePrescribing Task Group

  • -


Pharmacy Templates


PDex Formulary (Corey)

  • - Discuss Formulary Block vote 4
  • watch for block vote on Pharmacy list
  • one or two other issues.  once resolved and after block vote, next will be a request for publication

Pharmacist Consult Note (Scott)

FHIR (Group)

Trackers - link to pharmacy unresolved Jira trackers (see trackers for details / resolutions)

Any Other Business

Next meeting: May 30, 2022 June 6, 2022